Comprehensive Genomic Profiling Reveals Diverse but Actionable Molecular Portfolios across Hematologic Malignancies: Implications for Next Generation Clinical Trials
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Comprehensive Genomic Profiling Reveals Diverse but Actionable Molecular Portfolios across Hematologic Malignancies: Implications for Next Generation Clinical Trials
Authors
Keywords
-
Journal
Cancers
Volume 11, Issue 1, Pages 11
Publisher
MDPI AG
Online
2018-12-22
DOI
10.3390/cancers11010011
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD‐L1
- (2018) Lola Fashoyin‐Aje et al. ONCOLOGIST
- Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
- (2017) Richard M. Stone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
- (2017) Zachary R. Chalmers et al. Genome Medicine
- Tumor mutation load assessed by FoundationOne (FM1) is associated with improved efficacy of atezolizumab (atezo) in patients with advanced NSCLC
- (2016) M. Kowanetz et al. ANNALS OF ONCOLOGY
- Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting
- (2016) J. He et al. BLOOD
- Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study
- (2016) Jennifer J. Wheler et al. CANCER RESEARCH
- Effect of Sulindac and Erlotinib vs Placebo on Duodenal Neoplasia in Familial Adenomatous Polyposis
- (2016) N. Jewel Samadder et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Diffuse Large B-Cell Lymphoma Version 1.2016
- (2016) Andrew D. Zelenetz et al. Journal of the National Comprehensive Cancer Network
- Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience
- (2016) M. Schwaederle et al. MOLECULAR CANCER THERAPEUTICS
- Genomically Driven Tumors and Actionability across Histologies: BRAF-Mutant Cancers as a Paradigm
- (2016) M. L. Turski et al. MOLECULAR CANCER THERAPEUTICS
- ATM Mutations in Cancer: Therapeutic Implications
- (2016) M. Choi et al. MOLECULAR CANCER THERAPEUTICS
- Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
- (2016) Andrew W. Roberts et al. NEW ENGLAND JOURNAL OF MEDICINE
- Presence of isocitrate dehydrogenase mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia
- (2015) Ashkan Emadi et al. AMERICAN JOURNAL OF HEMATOLOGY
- MYD88 (L265P) Somatic Mutation in Marginal Zone B-cell Lymphoma
- (2015) Azahara Martinez-Lopez et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Prognostic relevance of MYD88 mutations in CLL: the jury is still out
- (2015) P. Baliakas et al. BLOOD
- VEGF-A Expression Correlates with TP53 Mutations in Non-Small Cell Lung Cancer: Implications for Antiangiogenesis Therapy
- (2015) M. Schwaederle et al. CANCER RESEARCH
- Molecular Pathways: Targeting the CXCR4-CXCL12 Axis--Untapped Potential in the Tumor Microenvironment
- (2015) S. Scala CLINICAL CANCER RESEARCH
- On the Road to Precision Cancer Medicine: Analysis of Genomic Biomarker Actionability in 439 Patients
- (2015) M. Schwaederle et al. MOLECULAR CANCER THERAPEUTICS
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- MYD88 Mutations and Response to Ibrutinib in Waldenström's Macroglobulinemia
- (2015) Steven P. Treon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia
- (2015) Enrico Tiacci et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Targeting CDK4 and CDK6: From Discovery to Therapy
- (2015) C. J. Sherr et al. Cancer Discovery
- The Molecular Signatures Database Hallmark Gene Set Collection
- (2015) Arthur Liberzon et al. Cell Systems
- The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis
- (2014) D L Boyle et al. ANNALS OF THE RHEUMATIC DISEASES
- TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients
- (2014) R. Bejar et al. BLOOD
- Unique Molecular Landscapes in Cancer: Implications for Individualized, Curated Drug Combinations
- (2014) J. Wheler et al. CANCER RESEARCH
- Molecular Tumor Board: The University of California San Diego Moores Cancer Center Experience
- (2014) M. Schwaederle et al. ONCOLOGIST
- Functional and cancer genomics of ASXL family members
- (2013) M Katoh BRITISH JOURNAL OF CANCER
- MYD88 expression and L265P mutation in diffuse large B-cell lymphoma
- (2013) Jung-Woo Choi et al. HUMAN PATHOLOGY
- Rapid Response to Vemurafenib in a Heavily Pretreated Patient With Hairy Cell Leukemia and a BRAF Mutation
- (2013) Javier Munoz et al. JOURNAL OF CLINICAL ONCOLOGY
- Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
- (2013) Garrett M Frampton et al. NATURE BIOTECHNOLOGY
- ATM signalling and cancer
- (2013) C A Cremona et al. ONCOGENE
- Targeting the BRAF V600E Mutation in Multiple Myeloma
- (2013) M. Andrulis et al. Cancer Discovery
- Recurrent Mutations of MYD88 and TBL1XR1 in Primary Central Nervous System Lymphomas
- (2012) A. Gonzalez-Aguilar et al. CLINICAL CANCER RESEARCH
- Targeting B-Cell Receptor Signaling for Anticancer Therapy: The Bruton's Tyrosine Kinase Inhibitor Ibrutinib Induces Impressive Responses in B-Cell Malignancies
- (2012) Adrian Wiestner JOURNAL OF CLINICAL ONCOLOGY
- Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial
- (2012) Jeffrey R Infante et al. LANCET ONCOLOGY
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- BRAFmutations in chronic lymphocytic leukemia
- (2012) Billy Michael Chelliah Jebaraj et al. LEUKEMIA & LYMPHOMA
- EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
- (2012) Michael T. McCabe et al. NATURE
- Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma
- (2012) Aleksandar Sekulic et al. NEW ENGLAND JOURNAL OF MEDICINE
- MYD88 L265P Somatic Mutation in Waldenström's Macroglobulinemia
- (2012) Steven P. Treon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular signatures database (MSigDB) 3.0
- (2011) A. Liberzon et al. BIOINFORMATICS
- DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia
- (2011) K H Metzeler et al. LEUKEMIA
- BRAFMutations in Hairy-Cell Leukemia
- (2011) Enrico Tiacci et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- BRAF, a target in melanoma
- (2010) Keith T. Flaherty et al. CANCER
- Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
- (2010) R. Eric Davis et al. NATURE
- PALB2 is an integral component of the BRCA complex required for homologous recombination repair
- (2009) S. M. H. Sy et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started